Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pharmarise HoldingsTSE:2796 -0.61%50 Days Payable is 38.15 as of May. 2026, which is 7% below its 10-year median of 40.85. GuruFocus rates TSE:2796 with a GF Score™ of 50/100 and a GF Value™ of 円608.01 (Modestly Undervalued). The stock has 10 warning signs investors should review. Among 607 Healthcare Providers & Services companies, Pharmarise Holdings ranks worse than 65.24% on this metric.
The historical rank and industry rank for Pharmarise Holdings's Days Payable or its related term are showing as below:
TSE:2796'
s Days Payable Range Over the Past 10 Years
Min: 34.76 Med: 40.85 Max: 44.92
Current: 39.73
During the past 13 years, Pharmarise Holdings's highest Days Payable was 44.92. The lowest was 34.76. And the median was 40.85.
TSE:2796's Days Payable is ranked worse than 65.24% of 607
companies
in the Healthcare Providers & Services industry
Industry Median: 57.13
vs TSE:2796: 39.73
Pharmarise Holdings's Days Payable
declined
from May. 2025 (38.91) to May. 2026 (38.15).
It may suggest that Pharmarise Holdingsaccelerated paying its suppliers.
Pharmarise Holdings Days Payable Related Terms
Pharmarise Holdings Days Payable Historical Data
* Premium members only.
The historical data trend for Pharmarise Holdings's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pharmarise Holdings Days Payable Competitor Comparison
For the Pharmaceutical Retailers subindustry, Pharmarise Holdings's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pharmarise Holdings Days Payable vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Pharmarise Holdings's Days Payable distribution charts can be found below:
* The bar in red indicates where Pharmarise Holdings's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Pharmarise Holdings's Days Payable for the fiscal year that ended in May. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pharmarise Holdings (TSE:2796) has a Days Payable of 38.15 as of May. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Pharmarise Holdings and its competitors. This is near median its historical median of 40.85. Over the past decade, Pharmarise Holdings' Days Payable has ranged from 34.76 to 44.92. According to the industry distribution chart, Pharmarise Holdings ranks #396 out of 607 companies in the Healthcare Providers & Services industry, placing it in the top 65.2%.
Is Pharmarise Holdings' Days Payable too high?
Pharmarise Holdings' current Days Payable of 38.15 is near median its 10-year median of 40.85. Over the past 10 years, this metric has ranged from a low of 34.76 to a high of 44.92. The Healthcare Providers & Services industry median Days Payable is 57.13. Pharmarise Holdings' value of 38.15 is 33.2% below this industry median. Based on the distribution chart, Pharmarise Holdings ranks #396 out of 607 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Pharmarise Holdings has a GF Score™ of 50/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pharmarise Holdings' Days Payable compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Pharmarise Holdings ranks #396 out of 607 companies for Days Payable. This places Pharmarise Holdings in the lower half of its industry. The industry median Days Payable is 57.13. Pharmarise Holdings' value of 38.15 is 33.2% below this benchmark. Historically, Pharmarise Holdings' own Days Payable has ranged from 34.76 to 44.92 over the past decade. While the company's 10-year median is 40.85 vs. the industry median of 57.13, Pharmarise Holdings has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Healthcare Providers & Services company?
The median Days Payable among Healthcare Providers & Services companies is 57.13, based on 607 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pharmarise Holdings's current Days Payable of 38.15 is 33.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Pharmarise Holdings and its competitors. For the Healthcare Providers & Services industry, the median Days Payable is 57.13 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pharmarise Holdings's current Days Payable is 38.15, which is near median its own 10-year median of 40.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharmarise Holdings stock overvalued right now?
Based on GuruFocus' analysis, Pharmarise Holdings (TSE:2796) is currently considered Modestly Undervalued. The stock's GF Value™ is 円608.01, compared to a current price of 円491.00 — trading 19.2% below its estimated fair value. The current Days Payable is 38.15, which is near median its 10-year median of 40.85 and 33.2% below the Healthcare Providers & Services industry median of 57.13. Pharmarise Holdings' overall GF Score™ is 50/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Pharmarise Holdings (TSE:2796), the current Days Payable is 38.15 as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pharmarise Holdings (TSE:2796) Overvalued in 2026?
Based on GuruFocus' analysis, Pharmarise Holdings stock appears to be undervalued.
The current stock price of 円491.00 is trading 19.2% below its estimated GF Value™ of 円608.01.
GuruFocus considers Pharmarise Holdings to be Modestly Undervalued.
Key valuation signals for TSE:2796:
Days Payable: 38.15 (near median its 10-year median of 40.85)
GF Value™: 円608.01 vs. price of 円491.00 (19.2% below fair value)
Industry Position: 33.2% below the Healthcare Providers & Services median (#396 of 607)
No single metric tells the full story. See the TSE:2796 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pharmarise Holdings Corp is engaged in the operation of dispensing pharmacies, which prescribe medicines to general patients based on the prescriptions issued by medical institutions. It is also engaged in the storage and management of medical examination records of patients on behalf of the medical institution.
50GF Score
Get the complete analysis for TSE:2796
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:2796 has been successfully added to your 
